WO2014055659A1 - Procédés et compositions pour la production de protéines recombinantes pharmaceutiques dans des plantes médicinales - Google Patents

Procédés et compositions pour la production de protéines recombinantes pharmaceutiques dans des plantes médicinales Download PDF

Info

Publication number
WO2014055659A1
WO2014055659A1 PCT/US2013/063086 US2013063086W WO2014055659A1 WO 2014055659 A1 WO2014055659 A1 WO 2014055659A1 US 2013063086 W US2013063086 W US 2013063086W WO 2014055659 A1 WO2014055659 A1 WO 2014055659A1
Authority
WO
WIPO (PCT)
Prior art keywords
plant
group
seq
genetically engineered
recombinant protein
Prior art date
Application number
PCT/US2013/063086
Other languages
English (en)
Inventor
Natalia Pogrebnyak
Vyacheslav Andrianov
Maxim Golovkin
Original Assignee
Pharma Green Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/849,154 external-priority patent/US9694068B2/en
Priority claimed from US13/922,719 external-priority patent/US9913890B2/en
Application filed by Pharma Green Llc filed Critical Pharma Green Llc
Publication of WO2014055659A1 publication Critical patent/WO2014055659A1/fr
Priority to IL237876A priority Critical patent/IL237876B/en
Priority to US14/673,914 priority patent/US20150197766A1/en
Priority to US16/012,394 priority patent/US20180280461A1/en
Priority to IL261409A priority patent/IL261409A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon

Definitions

  • the present disclosure relates to methods and compositions to produce recombinant proteins in medicinal plants.
  • the invention provides examples of genetically engineered plants of the genus Hydrastis, Echinacea, Thymus, Calendula or Kalanchoe comprising recombinant proteins, methods for producing recombinant proteins in such plants and corresponding plant-derived compositions. Methods of administering plant-derived compositions to subjects in need thereof are also described.
  • Plants can be utilized as a biotechnology platform for industrial production of recombinant proteins.
  • the advantages of plants compared to other production systems, e.g., bacteria, yeast, insect and mammalian cells, are lower production costs and the potential for easy scaling up production of large quantities of biomass.
  • An additional advantage of plant- derived compositions is that these are free of endotoxins or human pathogens.
  • Efforts to produce commercial pharmaceutical proteins in plants are mainly focused on utilizing model plant species that are easy to transform, e.g., tobacco and Arabidopsis, and crop species that can be used for food or animal feed, e.g., tomato, alfalfa, lettuce, carrot, potato, cauliflower, maize and rice. See Golovkin, 2011, Production of Recombinant Pharmaceuticals Using Plant Biotechnology, In: Bioprocess Science and Technology, Series Biochemistry Research Trends Ed. Min-Tze Liong. Nova Sci. Publ., Inc., USA.I SBN: 978-1- 61122-950; Gruskin, 2012 Nat Biotech 30: 211; and Pogrebnyak et al. 2006 Plant Sci 171: 677.
  • An aspect of the invention relates to a genetically engineered plant.
  • the plant belongs to the genus selected from the group consisting of: Hydrastis, Echinacea, Thymus, Calendula and Kalanchoe.
  • An aspect of the invention relates to a method for genetically engineering a plant.
  • the method includes contacting a plant with a vector comprising a nucleic acid encoding a recombinant protein.
  • the method also includes selecting a genetically engineered plant expressing the recombinant protein.
  • the plant belongs to the genus selected from the group consisting of: Hydrastis, Echinacea, Thymus, Calendula and Kalanchoe.
  • An aspect of the invention relates to a method for genetically engineering a plant.
  • the method includes obtaining a mutant plant.
  • the plant belongs to the genus selected from the group consisting of: Hydrastis, Echinacea, Thymus, Calendula and Kalanchoe.
  • An aspect of the invention relates to a method for producing a recombinant protein in a plant.
  • the method includes genetically engineering the plant to includes a nucleic acid encoding the recombinant protein.
  • the method also includes culturing a genetically engineered plant under conditions effective for expression a recombinant protein.
  • the plant belongs to the genus selected from the group consisting of: Hydrastis, Echinacea, Thymus, Calendula and Kalanchoe.
  • An aspect of the invention relates to a method of treating a subject against a disease.
  • the method includes genetically engineering a plant to include a nucleic acid encoding a recombinant protein capable of preventing, curing or eliminating at least one symptom of the disease in the subject.
  • the plant belongs to the genus selected from the group consisting of: Hydrastis, Echinacea, Thymus, Calendula and Kalanchoe.
  • the method includes harvesting a genetically engineered plant expressing the recombinant protein.
  • the method includes performing the step (i) or (ii).
  • the step (i) includes preparing a first composition that includes the genetically engineered plant, or a part thereof.
  • the step (ii) includes isolating the recombinant protein and preparing a second composition that includes the isolated recombinant protein.
  • the method also includes administering the first composition or the second composition to the subject in need thereof.
  • An aspect of the invention relates to a method of propagating a plant in vitro.
  • the method includes culturing a plant, or a part of the plant, on a culture medium that includes at least one plant growth regulator.
  • the method includes recovering multiple shoots from the plant or the part of the plant.
  • the plant belongs to the genus selected from the group consisting of: Hydrastis, Echinacea, Thymus, Calendula and Kalanchoe.
  • An aspect of the invention relates a method of producing a cell suspension culture.
  • the method includes culturing a plant, part, or tissue thereof, in a liquid culture medium that includes at least one auxin.
  • the plant belongs to the genus selected from the group consisting of: Hydrastis, Echinacea, Thymus, Calendula and Kalanchoe.
  • FIGS. 1A -1C illustrate development of in vitro propagation of
  • FIG. 1A illustrates multiple shoots induced from the leaf explants after six weeks of culturing on MSR1 medium with additional three weeks on MSR4.
  • FIG. IB illustrates shoot development from leaf tissues after 7 weeks of culturing on MSR3 medium.
  • FIG. 1C illustrates elongation of shoots developed from the leaf explants after transferring them to MSR4 medium.
  • FIG. 2 illustrates in vitro propagation of Thyme (Thymus vulgaris) under sterile conditions and climate-controlled environment.
  • FIG. 3 illustrates in vitro mass propagation of Echinacea (Echinacea purpurea) with multiple shoot regeneration events from leaf explants on MSR5 medium.
  • FIG. 4 illustrates in vitro development of multiple shoots from
  • Kalanchoe (Kalanchoe pinnatd) leaf explants on MSR6 medium.
  • FIG. 5 illustrates shoot regeneration from Calendula (Calendula officinalis) cotyledons on MSR3 medium.
  • FIGS. 6A - 6D illustrate in vitro initiation and propagation of callus and cell suspension.
  • FIG. 6A illustrates callus induction from leaf tissues after 6 weeks culturing on MSCl medium.
  • FIG.6B illustrates callus growth after 8 weeks culturing on MSC2 medium.
  • FIG.6C illustrates cell suspension after 2 weeks of culturing in liquid MS medium supplemented with 1 mg/12,4-D.
  • FIG.6D illustrates shoot regeneration from callus tissues after 8 weeks culturing on MSR3 medium.
  • FIGS. 7A - 7B illustrate formation of the transgenic Goldenseal shoots on the selection medium after Agrobacterium-mediated transformation.
  • FIG. 7A illustrates transgenic shoots developed on MST4 medium in the presence of kanamycin.
  • FIG. 7B illustrates the magnified shoots from FIG. 7A.
  • FIG. 8 illustrates the morphologically normal transgenic Goldenseal plant transplanted into soil.
  • FIG. 9 illustrates histochemical GUS analysis of transgenic
  • FIGS. 10A - IOC illustrate schematic drawings of binary pBI-based vectors prepared for stable transformation of plants via Agrobacterium tumefaciens.
  • FIG. 10A illustrates a vector for production of a TBL-Fc protein ATR-Fc.
  • FIG. 10B illustrates a vector for cyanovirin (CNVR) microbicide generation.
  • FIG. IOC illustrates a vector designed for production of the scytovirin (SCTV) microbicide.
  • FIGS. 11A - 11D illustrate generation and analysis of the transgenic Echinacea plants.
  • FIG. 11A illustrates the putative transgenic shoots.
  • FIG. 11B illustrates target gene-specific PCR analysis of putative transgenic Echinacea plants selected on Km selective media.
  • FIG.11C illustrates Western blot detection of the recombinant protein target by a polyclonal mouse primary antibody against the E. coZi-produced microbicide protein.
  • FIG. 11D illustrates detection of the recombinant CNVR protein using ELISA.
  • FIGS. 12A - 12B illustrate generation and analysis of the transgenic
  • FIG. 12A illustrates the stringency of selection.
  • FIG. 12B illustrates a target- specific detection of recombinant protein TBL in the extracts from the transgenic Kalanchoe plant lines using ELISA.
  • An embodiment herein provides a genetically engineered plant.
  • the genetically engineered plant may be a medicinal plant.
  • the genetically engineered plant may belong to but is not limited to genus Hydrastis, Echinacea, Thymus, Calendula or Kalanchoe.
  • the genetically engineered plant may be Hydrastis canadensis.
  • the genetically engineered plant may be Echinacea purpurea.
  • the genetically engineered plant may be Thymus vulgaris.
  • the genetically engineered plant may be Calendula officinalis.
  • the genetically engineered plant may be Kalanchoe pinnata.
  • the plant may be genetically engineered to include a nucleic acid encoding a recombinant protein.
  • the nucleic acid may be an exogenous nucleic acid.
  • the exogenous nucleic acid may include genetic material not found in a native medicinal plant.
  • the exogenous nucleic acid may include multiple exogenous nucleic acids. Multiple exogenous nucleic acids may originate from multiple sources or organisms.
  • the nucleic acid may be generated recombinantly or synthetically, with a series of specified nucleic acid elements, which permit transcription of a particular nucleic acid in plant cells and plant tissues.
  • the nucleic acid may be incorporated into a plasmid, chromosome, mitochondrial DNA, plastid DNA, virus or nucleic acid fragment.
  • the nucleic acid may include an open reading frame encoding a recombinant protein.
  • the recombinant protein may be a pharmaceutical protein.
  • the pharmaceutical protein may be any protein to treat diseases.
  • the pharmaceutical protein may be a microbicide.
  • microbicide refers to any compound or substance capable of reducing the infectivity of microbes. Microbicides may reduce infectivity of viruses or bacteria. For example, microbicides may be applied inside the vagina or rectum to protect against sexually transmitted infections including human immunodeficiency virus (HIV). They may be formulated as gels, creams, films, or suppositories, used for preventing transmission of HIV.
  • the microbicide may be griffithsin produced by red algae. See Mori et al.
  • the microbicide may be a cyanovirin as described by Huskens and Schols. See Huskens and Schols, 2012, Algal Lectins as Potential HIV Microbicide Candidates, Marine Drugs, 10, 1476-1497, which is incorporated herein by reference as if fully set forth.
  • the amino acid sequence of the cyanovirin may be optimized for targeting apoplast.
  • the cyanovirin may include, consist essentially of, or consist of a sequence with at least 70, 72, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identity to a reference sequence of SEQ ID NO: 1
  • the microbicide may be scytovirin.
  • the amino acid sequence of the scytovirin may be optimized for targeting apoplast.
  • the scytovirin may include, consist essentially of, or consist of a sequence with at least 70, 72, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identity to a reference sequence of SEQ ID NO: 3.
  • the recombinant protein may be an antibody effective for eliminating or reducing the size of tumors in a subject having cancer.
  • the antibody may have an ability to recognize and specifically bind to a target molecule associated with cells, tissues or organs affected by a disease.
  • the target molecule may be a protein, a polypeptide, a peptide, a carbohydrate, a polynucleotide, a lipid, or combinations of at least two of the foregoing through at least one antigen recognition site within the variable region of the antibody.
  • the antibody may specifically bind to a cancer stem cell marker protein and interfere with, for example, ligand binding, receptor dimerization, expression of a cancer stem cell marker protein, and/or downstream signaling of a cancer stem cell marker protein.
  • the antibody may be an anthrax toxin binding recombinant antibody.
  • the anthrax toxin binding recombinant antibody may include a toxin binding ligand.
  • the toxin binding ligand may be capable of binding anthrax toxin with high affinity.
  • the toxin binding ligand may be a human or animal anthrax receptor (ATR) protein.
  • the toxin binding ligand may be a capillary morphogenesis protein 2 (CMG-2).
  • the toxin binding ligand may be a soluble domain of the CMG-2.
  • the toxin binding ligand may be a soluble domain of another ATR protein.
  • the toxin binding ligand may be a soluble domain of another anthrax toxin-binding polypeptide.
  • the toxin binding ligand may be a polypeptide capable of high affinity binding to a protective antigen (PA) region necessary for PA interaction with a lethal factor (LF) or an edema factor (EF) components of the anthrax toxin.
  • PA protective antigen
  • LF lethal factor
  • EF edema factor
  • PA-LF protective antigen binding domain of a lethal factor
  • the antibody may be a polyclonal antibody, an intact monoclonal antibody, an antibody fragment or fusion, which may be, but is not limited to, Fab, Fab', F(ab')2, an Fv fragment, a single chain Fv (scFv) mutant, a chimeric antibody or a multi- specific antibody.
  • a multi- specific antibody may be a bi- specific antibody generated from at least two intact antibodies.
  • the antibody may be a humanized antibody or a human antibody.
  • the antibody may be a fusion protein comprising an antigen determination portion of an antibody.
  • the antibody may be a fusion chimeric antibody against anthrax toxin consisting of anthrax Toxin Binding Ligand (TBL) polypeptide fused with Fc fragment of IgG, IgA or IgM antibody.
  • TBL Thrax Toxin Binding Ligand
  • the recombinant protein may be an antigen.
  • the term "antigen" refers to a molecule that is capable of stimulating a recipient's immune system to produce an antigen- specific response, i.e., an immune response. Such an immune response may be a cellular immune response to an antigenic site present and/or a humoral immune response.
  • the antigens may be virus coat proteins or membrane proteins.
  • the viral coat proteins may include but are not limited to LI, B5 and A33 Vaccinia virus proteins.
  • the antigen may be a Vaccinia virus glycoprotein B5 membrane antigen.
  • the antigens may be capable of eliciting an immune response against poxvirus.
  • the antigens may be capable of eliciting an immune response against Vaccinia virus.
  • the genetically engineered plant may include a nucleic acid sequence optimized for protein expression in plants.
  • the optimized sequence may enhance expression of an exogenous polynucleotide in plants.
  • the optimized nucleic acid sequence may include plant optimized codon sequences.
  • the nucleic acid may include, consist essentially, or consist of a sequence with at least 70, 72, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identity to a reference sequence selected from the group consisting of: SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6.
  • Determining percent identity of two amino acid sequences or two nucleic acid sequences may include aligning and comparing the amino acid residues or nucleotides at corresponding positions in the two sequences. If all positions in two sequences are occupied by identical amino acid residues or nucleotides then the sequences are said to be 100% identical. Percent identity may be measured by the Basic Local Alignment Search Tool (BLAST; Altschul, S.F., Gish, W., Miller, W., Myers, E.W. & Lipman, D.J, 1990 "Basic local alignment search tool.” J. Mol. Biol. 215:403-410, which is incorporated herein by reference as if fully set forth).
  • BLAST Basic Local Alignment Search Tool
  • the recombinant protein may be a variant.
  • Variants may include conservative amino acid substitutions, i.e., substitutions with amino acids having similar properties.
  • Conservative substitutions may be a polar for polar amino acid (Glycine (G), Serine (S), Threonine (T), Tyrosine (Y), Cysteine (C), Asparagine (N) and Glutamine (Q)); a non-polar for non-polar amino acid (Alanine (A), Valine (V), Thyptophan (W), Leucine (L), Proline (P), Methionine (M), Phenilalanine (F)); acidic for acidic amino acid Aspartic acid (D), Glutamic acid (E)); basic for basic amino acid (Arginine (R), Histidine (H), Lysine (K)); charged for charged amino acids (Aspartic acid (D), Glutamic acid (E), Histidine (H), Lysine (K) and Arginine (R)); and a hydrophobic for hydrophobic amino acid (Alanine (A),
  • the recombinant protein may include a full length protein or a fragment.
  • the fragment of the recombinant protein refers to a subsequence of the polypeptides herein that retain the biological function of the full length protein.
  • fragments of a cyanovirin, a scytovirin, an anthrax toxin binding recombinant antibody or a Vaccinia virus glycoprotein B5 membrane antigen are provided. Fragments may include 50, 100, 150, 200, 300, 400, 600, or 700 contiguous amino acids or more.
  • the functionality of a recombinant protein, variants or fragments thereof may be determined using any methods.
  • the functionality may include conferring ability to bind the components of the anthrax toxin in a solution as determined by immunodetection methods.
  • the functionality may be assessed in vitro using biochemical assays or live cells.
  • the functionality of a protein, or variants, or fragments thereof may be assessed based on the ability to protect subjects following of the infection of subjects with the causative agent.
  • the functionality of a protein, or variants, or fragments thereof may be assessed based on the ability to protect subjects after administering of a recombinant antitoxin following of the infection of animals with the causative agent of anthrax.
  • the functionality may be assessed based on the ability to inhibit poxvirus.
  • Assessment of functionality of proteins may include a virus neutralization assay which includes incubation of a virus titer with serial dilutions of serum obtained from an animal after periodic administering of an immunogenic protein and quantifying the amount of the remaining virus by, e.g., plaque "comet inhibition” assay (Isaacs et al., 1992 J Virol 66:7217; Aldaz-Carroll et al., 2005 J Virol. 79:6260; Xiao et al., 2006 Vaccine 25:1214, all of which are incorporated by reference herein as if fully set forth).
  • a method for genetically engineering a plant may include contacting a plant with a vector.
  • the vector may include a nucleic acid encoding a recombinant protein.
  • the method may include selecting a genetically engineered plant expressing the recombinant protein.
  • the plant may be genetically engineered using transformation.
  • the nucleic acid may be introduced into a genetic vector.
  • Suitable vectors may be cloning vectors, transformation vectors, expression vectors, or virus-based vectors.
  • the expression cassette portion of a vector may further include a regulatory element operably linked to at least one of the first polynucleotide, the second polynucleotide or the third polynucleotide.
  • operably linked means that the regulatory element imparts its function on the nucleic acid.
  • a regulatory element may be a promoter, and the operably linked promoter would control overexpression of the nucleic acid.
  • the expression of the nucleic acid of the expression cassette may be under the control of a promoter which provides for transcription of the nucleic acid in a plant.
  • the promoter may be a constitutive promoter or, tissue specific, or an inducible promoter.
  • a constitutive promoter may provide transcription of the nucleic acid throughout most cells and tissues of the plant and during many stages of development but not necessarily all stages.
  • An inducible promoter may initiate transcription of the nucleic acid sequence only when exposed to a particular chemical or environmental stimulus.
  • a tissue specific promoter may be capable of initiating transcription in a particular plant tissue. Plant tissue may be, but is not limited to, a stem, leaves, trichomes, anthers, or seed.
  • Constitutive promoter may be, but is not limited to, the Cauliflower Mosaic Virus (CAMV) 35S promoter, the Cestrum Yellow Leaf Curling Virus promoter (CMP), the CMP short version (CMPS), the Rubisco small subunit promoter, or the maize ubiquitin promoter.
  • the plant may be genetically engineered by stable transformation, wherein the nucleic acid encoding the recombinant protein integrates into a genome of the transformed plant.
  • the genetically engineered plant may be created by Agrobacterium-medi&ted transformation using a vector suitable for stable transformation described herein.
  • the genetically engineered plant may be created by any other methods for transforming plants, for example, particle bombardment, or protoplast transformation via direct DNA uptake.
  • the genetically engineered plant may include any isolated nucleic acids, amino acid sequences, expression cassettes, or vectors herein.
  • the plant may be genetically engineered to transiently express the recombinant protein.
  • transient expression refers to the expression of an exogenous nucleic acid molecule delivered into a cell, e.g., a plant cell, and not integrated in the plant's cell chromosome. Expression from extra-chromosomal exogenous nucleic acid molecules can be detected after a period of time following a DNA-delivery.
  • Virus-based vectors may be used to carry and express exogenous nucleic acid molecules. Virus-based vectors may replicate and spread systemically within the plant. Use of virus based vectors may lead to very high levels of protein accumulation in genetically engineered plants.
  • the plant may be genetically engineered to be a conventional mutant having one or more mutations in a nucleic acid sequence encoding a protein involved in regulating levels of a compound or compounds conferring medicinal properties to the plant.
  • the mutations may be deletions, insertions, modifications, or substitutions of nucleic acids in a sequence of the target genes.
  • the mutant plant may be created by mutagenizing plant seeds, e.g., by chemical mutagenesis (EMS) or radiation, and selecting the mutants by PCR amplification and sequencing the mutant PCR product.
  • the mutant plant may be created by using mutagenesis and screening strategies such as Targeted Induced Lesions In Genomics (TILING), T-DNA insertion and transposon-based mutagenesis.
  • TILING Targeted Induced Lesions In Genomics
  • the mutant plant may be genetically engineered through site directed mutagenesis. See Voytas 2013 Annual Review of Plant Biology 64: 327, which is incorporated herein as if fully set forth.
  • the mutant plant may be genetically engineered through somaclonal variation resulted from exposing plants or plant explants to in vitro tissue culture conditions, e.g., plant growth regulators, auxins or cytokinins.
  • the mutant plant may be, for example, Goldenseal plant with enriched levels of compounds conferring medicinal properties.
  • the mutant Goldenseal plant may include elevated levels of alkaloids, e.g., berberine, ⁇ -hydrastine, canadine and schemaline, compared to the levels of such alkaloids observed in non- mutant wild type plants.
  • the mutant plant may be a mutant Echinacea plant.
  • the mutant Echinacea plant may include elevated levels of active ingredients including alkamides, flavonoids, essential oils, and polyacetylenes.
  • the mutant plant may be a mutant Kalanchoe plant.
  • the mutant Kalanchoe plant may have elevated levels of kaempferol and quercetin.
  • the genetically engineered plant may be a whole plant, or a part of a plant.
  • the part of a plant may be, but is not limited to, a stem, a leaf, a flower, a seed, or a callus.
  • the genetically engineered plant may be a progeny, or descendant of a genetically engineered plant.
  • the genetically engineered plant may be obtained through crossing of a genetically engineered plant and a non- genetically engineered plant as long as it retains the exogenous or modified nucleic acid as described above.
  • a method for producing a recombinant protein in a plant may include a step of genetically engineering a plant to include a nucleic acid encoding a recombinant protein.
  • the method may further include culturing the plant under conditions effective for expression of the recombinant protein.
  • the method of genetically engineering the plant may include stably transforming the plant using Agrobacterium-medi&ted transformation, or transiently expressing the recombinant proteins by methods described herein.
  • the method may further include isolating and purifying the recombinant protein.
  • the recombinant protein may be any therapeutically effective protein.
  • therapeutically effective protein refers to a protein capable of generating an appearance of antigen- specific antibodies, such as in serum, or remediation of disease symptoms when applied to a subject in need thereof.
  • the therapeutically effective proteins may be but are not limited to microbicides, vaccines, antibodies, antigens, growth factors, transcription factors, or enzymes.
  • Therapeutic efficacy and toxicity of active agents in a composition may be determined by standard pharmaceutical procedures, for example, by determining the therapeutically effective dose in 50% of the population (ED50) and the lethal dose to 50% of the population (LD50) in cells cultured in vitro or experimental animals. Plant-derived compositions may be evaluated based on the dose ratio of toxic to therapeutic effects (LD59/ED50), called the therapeutic index, the large value of which may be used for assessment. The data obtained from cell and animal studies may be used in formulating a dosage for human use.
  • the therapeutic dose shown in examples herein may be at least one microgram ( ⁇ g), or about 3 x 1 ⁇ g, or about 10 x 1 ⁇ 3 ⁇ 4 unit of antigen/dose/animal.
  • ⁇ g microgram
  • plant-based vaccines may be readily produced and inexpensively engineered and designed and stored, greater doses for large animals may be economically feasible.
  • the dose may be easily adjusted, for example, to about 3 x 10 x 1 ⁇ g, or about 3 x 20 x 1 ⁇ g, or about 3 x 30 x 1 ⁇ g for animals such as humans and small agricultural animals.
  • doses of about 3 x 40 x 1 ⁇ g, 3 x 50 x 1 ⁇ g or even about 3 x 60 x 1 ⁇ g, for example, for a high value zoo animal or agricultural animal such as an elephant may be provided.
  • smaller doses such as less than about 3 x 1 ⁇ g, 1 ⁇ g and less than about 0.5 ⁇ g per dose, may be provided (Portocarrero, 2008 Vaccine 26: 5535, which is incorporated herein by reference as if fully set forth).
  • a method of treating a subject against a disease may include genetically engineering a plant to include a nucleic acid encoding a recombinant protein capable of preventing, curing the disease, or eliminating at least one symptom of the disease in the subject.
  • the method may include harvesting the genetically engineered plant.
  • the plant genetically engineered to express the recombinant protein may be applied directly, i.e., without or with a little processing, to skin or mucosal surfaces of a subject.
  • the genetically engineered plants may be used as herbal products, i.e., as cut and powdered roots, tinctures, fluid extracts, powdered extract, pharmaceutically processed capsules, tablets, creams, and salves.
  • Medicinal plants may enhance the potency of pharmaceutical compositions, for example, by eliminating irritation, inflammation, sensitization and dryness if such compositions are applied topically or to mucosal surfaces of the recipients.
  • the genetically engineered plant, or part of a plant may be included in a first composition.
  • the first composition may be a liquid that include a diluted extract prepared from the genetically engineered plant.
  • the first composition may be herbal tea resultant from extracting genetically engineered plant into water.
  • the herbal tea may be an infusion.
  • the infusion may be the hot water extract of the genetically engineered plant.
  • the herbal tea may be a decoction.
  • the decoction may be the long-term boiled extract of the genetically engineered plant.
  • the first composition may be a tincture.
  • the tincture may be an alcoholic extract of the genetically engineered plant.
  • the extracts of the genetically engineered plants may be liquid extracts.
  • the extracts of the genetically engineered plants may be dry extracts. Dry extracts may be prepared from the tincture that includes the genetically engineered plant which is evaporated into a dry mass. Dry extracts may be further refined to a capsule or tablet.
  • the method may include contacting the subject with a first composition comprising the recombinant plant, or part thereof.
  • the method may include isolating the recombinant protein.
  • the method may further include preparing the second composition that includes the isolated recombinant protein.
  • the second composition may be administered in a formulation with an appropriate pharmaceutically acceptable carrier in a desired dosage.
  • the second composition may be administered in liquid dosage forms.
  • Liquid dosage forms may be prepared for nasal administration.
  • Liquid dosage forms for nasal administration may include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, and suspensions.
  • Liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils cottonseed, groundnut, corn, germ, olive, castor, sesame oils, glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
  • inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol,
  • the nasal compositions may also include adjuvants.
  • Liquid dosage forms for nasal administration may be aqueous drops, a mist, an emulsion, or a cream.
  • Dosage forms for topical or transdermal administration of the second composition may include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants, or patches.
  • Ointments, pastes, creams, lotions, gels may contain other natural constituents of plant cells. The other natural constituents of plant cells may have a synergistic effect in treating the subject.
  • Ointments, pastes, creams, lotions, gels may contain vitamins, ethers, oils, or polysaccharides.
  • Powders and sprays may contain recombinant proteins admixed with excipients such as talc, silicic acid, zinc oxide, sulfur, aluminum hydroxide, calcium silicates, polyamide powder, or mixtures of these substances.
  • Sprays may additionally contain customary propellants, for example, chlorofluorohydrocarbons.
  • the recombinant proteins may be admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be appropriate.
  • the second composition for may be formulated for rectal or vaginal administrations and include suppositories.
  • Suppositories may be prepared by mixing of the recombinant proteins with suitable non-irritating excipients or carriers.
  • the excipients may include natural component of plant oils.
  • the excipients may include cocoa butter.
  • the excipients may include natural complex polysaccharides derived from plants.
  • the excipients may derive from Aloe, Yerba santa, or algae.
  • the excipients may be a conventional polyethylene glycol or a suppository wax.
  • the carriers may be solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the recombinant proteins.
  • the method may include contacting the subject with the second composition comprising the recombinant protein.
  • the term "subject” refers to a mammal.
  • a subject may be male or female mammal.
  • a mammal may be an animal or a human.
  • the term "subject” does not denote a particular age. Thus, both adult and newborn individuals are intended to be covered.
  • the compositions described herein are intended for use in any of the above subjects, since the immune systems of all of these subjects operate similarly.
  • the composition may be therapeutically effective.
  • Therapeutic efficacy may depend on effective amounts of active agents and time of administering necessary to achieve the desired result.
  • Active agents may be recombinant proteins.
  • Administering a composition may be a prophylactic or preventive measure.
  • Administering of a composition may be a therapeutic measure to promote immunity to the infectious agent, to minimize complications associated with the slow development of immunity especially in patients with a weak immune system, elderly or infants.
  • the plant-derived composition may be provided in a "therapeutically effective amount," i.e., the amount sufficient to generate appearance of antigen- specific antibodies in serum, or disappearance of disease symptoms. Disappearance of disease symptoms may be assessed by a decrease of virus in feces or in bodily fluids or in other secreted products.
  • the exact dosage of the composition may be chosen based on a variety of factors and in view of individual characteristics of subjects. Dosage and administration may be adjusted to provide sufficient levels of the active agent or agents or to maintain the desired effect. For example, factors which may be taken into account include the type and severity of a disease; age and gender of the subject; drug combinations; and an individual response to therapy.
  • the active agent may be a recombinant protein.
  • the recombinant protein may be a microbicide, an antigen or an antibody.
  • compositions described herein may be administered using any amount and any route of administration effective for generating an antibody response.
  • the compositions that include medicinal plants may be applied topically to skin or to mucosal surfaces of a subject.
  • a mucosal route may include administering plant- derived composition to any mucosal surface of the body of the subject.
  • Mucosal surfaces may include oral, lingual, sublingual, intranasal, ocular, vaginal, urethral and rectal surfaces.
  • Mucosal administration differs from "systemic" or "parenteral” administration.
  • Systemic administration may include administering compositions to a non-mucosal surface, e.g., intraperitoneal, intramuscular, cutaneous, sub-, or transcutaneous, intra- or transdermal, or intravenous administration.
  • Goldenseal- derived compositions comprising
  • Goldenseal plants or components of the Goldenseal plants may be used for treating a variety of diseases including, but not limited to, colds, whooping cough, pneumonia, chronic constipation, hepatic congestion, cerebral engorgements, leucorrhea, and gallstones.
  • Goldenseal- derived compositions may be also applied for treatment of digestive disorders, peptic ulcers, gum diseases, sinusitis, catarrhal deafness, tinnitus, and pelvic inflammatory disorders, along with a variety of other diseases.
  • the Goldenseal properties may allow use of goldenseal- derived compositions to treat vaginal infection, eczema, conjunctivitis, eliminate irritation, inflammation, sensitization and dryness.
  • Echinacea- derived compositions comprising
  • Echinacea plants or components of the plants may be used for treating a variety of diseases including, but not limited to, infections, urinary tract infections, vaginal infections, ear infections, wounds, skin infections, inflammatory skin conditions, fever, malaria, and blood poisoning.
  • Kalanchoe-derived compositions comprising
  • Kalanchoe plants or parts of Kalanchoe plants may be used for treating various respiratory conditions, such as asthma, coughs and bronchitis.
  • Kalanchoe may be used for treating rheumatism, inflammation, gastric ulcers, infections, and pain.
  • a Kalanchoe leaf infusion or juice may be used for treatments of headaches, toothaches, earaches, eye infections, wounds, ulcers, boils, burns and insect bites.
  • Kalanchoe preparations may be used in surgical, stomatological, and obstetric- gynecological practice [0076]
  • Calendula-derived compositions comprising
  • Calendula plant or parts of Calendula plants may be used for treating upset stomach, ulcers, hemorrhoids, inflammations, and wounds.
  • Thyme-derived compositions comprising Thyme plants or parts of Thyme plants may be used treating coughs, bronchitis, and inflammation of upper respiratory membranes.
  • compositions herein may be used to treat or prevent a disease or an abnormal condition in a subject.
  • An abnormal condition refers to a function in the cells and tissues in a body of a subject that deviates from the normal function in the body.
  • An abnormal condition may refer to a disease.
  • the disease may be but is not limited to acquired immunodeficiency syndrome (AIDS), anthrax, smallpox, SARS avian flu, hepatitis B, DTP, RSV, papillomavirus, and cancer.
  • AIDS acquired immunodeficiency syndrome
  • anthrax smallpox
  • SARS avian flu hepatitis B
  • DTP hepatitis B
  • RSV papillomavirus
  • a plant-derived composition expressing microbicides may be administered to a subject to protect the subject against development of AIDS.
  • a plant-derived immunogenic composition expressing a Vaccinia glycoprotein B5 membrane antigen may be administered for immunizing subjects for resistance against poxvirus associated illnesses. See Golovkin et al. 2007 Proc Natl Acad Sci U S A 104: 6864, which is incorporated herein as if fully set forth.
  • treatments of a variety of infectious diseases arising from infection with Vaccinia virus, variola virus, monkeypox virus, raccoon poxvirus, skunk poxvirus, camelpox virus, ectromelia virus, cowpox virus, taterapox virus and volepox virus are provided.
  • administering of a plant-derived therapeutic composition may be a preventive treatment of subjects to promote emergency post-infection prophylaxis of a contact with the infectious agent.
  • Administering of a plant-derived composition may be a therapeutic measure for neutralization anthrax toxin produced by bacterial pathogen Bacillus anthracis and minimizing complications associated with accumulation of deadly toxin in patients infected with the pathogen bacteria.
  • Administering the plant-derived composition may be used for treatment of a variety of, symptoms and consequences of various forms of anthrax disease arising from infection with pathogenic bacteria Bacillus anthracis.
  • Plant-derived therapeutic compositions may be useful to treat patients being in contact with anthrax toxin, pathogen, infected animal or human, belonging to a group of risk of biological weapon attack.
  • the method may further include measuring cell viability in the presence of different concentrations of the anthrax toxin, wherein cell viability is a percentage of surviving cells protected by the antitoxin in comparison to the complete lysis in the control.
  • the method may further include measuring survival of animals after challenging with lethal concentration of the anthrax toxin or B. anthracis spores, followed by administration of protective amounts of the recombinant antitoxin.
  • the survival may be a percentage of live animals protected by the antitoxin in comparison to unprotected objects in the control.
  • a method of propagating a plant in vitro is provided.
  • the plant may belong to the genus selected from the group consisting of Hydrastis, Echinacea, Thymus, Calendula, and Kalanchoe.
  • the method may include culturing a plant, or part of the plant on a culture medium.
  • the culture medium may include one or more plant growth regulators.
  • the method includes recovering multiple shoots grown from the plant or the part of the plant.
  • plant growth regulators or "plant hormones” refers to chemicals or a group of chemicals that are used in plant cell culture media to facilitate plant growth.
  • the plant growth regulator may be a cytokinin.
  • the cytokinin may be but is not limited to kinetin, benzylaminopurine (BAP), zeatin, and thidiazuron. Cytokinins are known to induce shoot formation from plant explants.
  • the plant growth regulator may be an auxin.
  • the auxin may be, but is not limited to, indole-butyric acid (IBA), indole-acetic acid (IAA), naphthalene acetic acid (NAA) and 2,4- dichlorophenoxy- acetic acid (2,4- D).
  • IBA indole-butyric acid
  • IAA indole-acetic acid
  • NAA naphthalene acetic acid
  • 2,4- dichlorophenoxy- acetic acid 2,4- dichlorophenoxy- acetic acid
  • Auxins may be combined with cytokinins to induce shoot formation from plant explants. Auxins may facilitate callus formation from plant explants.
  • a culture medium may have combinations of auxins and cytokinins in different concentrations during different stages of shoot development. Multiple shoots may be produced on the culture medium.
  • shoots may be excised.
  • the excised shoots may be further rooted in a rooting medium.
  • the rooting medium may be a hormone free- medium.
  • the excised shoots may be rooted in a medium that includes an auxin.
  • the excised shoots may be rooted in any other way. For example, shoots may be rooted in soil under the greenhouse conditions.
  • a method of producing a cell suspension culture derived from a plant, part or tissue thereof may include culturing plant, part or tissue thereof in a liquid medium.
  • the liquid medium may include an auxin.
  • the auxin may be but is not limited to IBA, IAA, NAA and 2,4-D.
  • the auxin may be 2, 4-D.
  • the cell suspensions cultures may be kept in the dark.
  • the cell suspension cultures may be agitated during culturing.
  • the cell suspension cultures may be further used for propagation of the plants.
  • in vitro propagation methods and tissue culture may be developed for mass multiplication of many important medicinal plants. Development of efficient tissue culture protocols for Goldenseal, Echinacea, Thymus, Calendula, and Kalanchoe, may allow production of sufficient plant material for commercial purposes. Efficient mass propagation, both, as whole plants, and as cell cultures may be established and may serve as a basis for the development of a protocol for genetic transformation. Plants produced by in vitro propagation may be characterized by a uniform quality and significant increase in biomass yields.
  • Goldenseal (Hydrastis canadensis), a member of the Ranunculaceae family, has been traditionally used for treating a variety of diseases and illnesses such as whooping cough, pneumonia, chronic constipation, hepatic congestion, cerebral engorgements, leucorrhea, and gallstones.
  • Goldenseal is considered effective for treating the mucosal surfaces lining the mouth, throat, intestines, stomach, urinary tract, vagina and rectum. See Foster and Tyler 1999 Tyler's Honest Herbal: A sensible guide to the use of herbs and related remedies. Binghamton, NY, The Haworth Herbal Press.
  • Goldenseal is a small perennial herb, native to southeastern Canada and the northeastern US. Goldenseal's popularity has led to overharvesting in the wild.
  • Development of tissue culture techniques for mass propagation is desired to restore the population of the plant and for commercial uses.
  • commercial preparations of wild harvested goldenseal might contain environmental pollutants, particularly, the heavy metals. See Liu et al. 2004 In Vitro Cell Dev Biol Plant 40:75. Plants grown in vitro evade the problem of environmental pollutants, microbial infestations, and soil-born contaminants.
  • Echinacea (Echinacea purpurea), a member oiAsteraceae family, is a perennial herb native to the Midwestern region of the U.S.A. Historically, Echinacea had been used by Native Americans to treat infections and wounds, fever, malaria, blood poisoning, syphilis and diphtheria. Echinacea is known to alleviate symptoms of the common cold and flu, such as sore throat, cough, and fever, and shorten the duration of the disease.
  • the active ingredients of Echinacea purpurea include caffeic acid derivatives, alkamides, flavonoids, essential oils, and polyacetylenes.
  • Echinacea is an attractive plant for mucosal and topical applications, and can be used alone or in formulations for treating vaginal and urinary tract infections, ear infections, for healing wounds, burns, skin infections and inflammatory skin conditions.
  • Kalanchoe pinnata Another medicinal plant, Kalanchoe (Kalanchoe pinnata), is a member of the Crassulaceae family, that is cultivated in the U.S. as an ornamental plant. Kalanchoe had a history of use for treating various respiratory conditions, such as asthma, coughs and bronchitis. Kalanchoe use was reported for treating rheumatism, inflammation, gastric ulcers, infections, and pain. A leaf infusion or juice is used for treatments of headaches, toothaches, earaches, eye infections, wounds, ulcers, boils, burns and insect bites.
  • Kalanchoe preparations are used in surgical, stomatological and obstetric- gynecologic practice, and reported to be efficient for topical and mucosal applications including oral, intranasal, vaginal, and rectal application.
  • Coumaric, ferulic, syringic, caffeic and phydroxybenzoic acids, kaempferol and quercetin were detected in Kalanchoe leaves.
  • Calendula Calendula officinalis
  • an annual plant native to
  • Calendula has been used to treat stomach upset, ulcers, hemorrhoids, inflammations, and wounds.
  • the flower petals of the calendula plant have been used for medicinal purposes since at least the 12th century.
  • the antiinflammatory effects have been reported to be due to the triterpenoids, and specifically faradiol, found in calendula.
  • Calendula preparations are used for healing wounds, including traumatic wounds and chronic wounds, such as pressure sores and diabetic ulcers.
  • Calendula includes high levels of flavonoids, plant-based antioxidants that protect cells from free radicals.
  • Calendula preparations are applied to the skin to help burns, bruises, and cuts heal faster, and to fight the minor infections they cause. Calendula preparations are efficiently using for mucosal applications, particularly, for the oral and pharyngeal mucosa, as well as for vaginal and rectal mucosal surfaces.
  • Thyme Thymus vulgaris
  • Thyme belongs to the Lamiaceae family. Thyme has been reported for medicinal uses for thousands of years. Traditional uses of thyme include treatments of coughs, bronchitis, and catarrh, i.e., inflammation of upper respiratory tract mucous membranes. Thyme essential oil contains a range of compounds, such as p-Cymene, myrcene, borneol and linalool. Thyme oil is also reported to contain 20-54% of thymol. The Thyme flowers, leaves, and oil are used in herbal medicine. Topically, Thyme has been used for bald patches, laryngitis, tonsillitis, and mouth inflammation, and Thyme preparations are used for topical and mucosal applications.
  • tissue culture technologies developed herein may be useful for development of improved lines of medicinal plants enriched in valuable compounds and characterization of these compounds, such as alkaloids hydrastine and berberine of Goldenseal, alkamides, flavonoids, essential oils, and polyacetylenes of Echinacea and kaempferol and quercetin of Kalanchoe.
  • tissue culture approaches were utilized including in vitro propagation, callus initiation, cell suspension, and plant regeneration.
  • Transformation systems for medicinal plants have been developed including stable transformation and transient expression.
  • Transgenic Hydrastis, Echinacea, Thymus, Calendula, and Kalanchoe plants with high expression of recombinant proteins have been produced.
  • For stable transformation of Hydrastis, Echinacea, Thymus, Calendula, and Kalanchoe Agrobacterium- mediated methods were used as well as particle bombardment technology. These technologies may be used for other medicinal plants.
  • Medicinal plants can be used for production and direct delivery of commercial, industrial, cosmetic and pharmaceutical proteins including microbicides, vaccines, antibodies and many others. Moreover, due to valuable medicinal properties, Goldenseal, Echinacea, Calendula, Kalanchoe and Thyme are attractive plant systems for mucosal application. Preparations of these medicinal plants can be applied directly without purification. Data herein open new opportunities to utilize medicinal plants as a platform for production and delivery of recombinant proteins.
  • Kalanchoe, Thyme and Calendula have been sterilized and cultured in vitro.
  • cotyledons and leaf segments of these medicinal plants were placed into 100x15 mm Petri dishes containing 25 ml of MS medium supplemented with plant hormones (Murashige and Skoog 1962 Physiol Plant 15: 473).
  • cytokinins 6-bezylaminopurine (BAP: 0.5, 1, and 2 mg/1), kinetin (0.5 - 1 mg/1), zeatin (0.5 - 1 mg/1), thidiazuron (TDZ; 0.5, 1 and 2 mg/1), and auxins: naphtaleneacetic acid (NAA; 0.1, 0.2, 0.3, and 0.5 mg/1) and 2,4-dichlorophenoxyacetic acid (2,4-D; 0.1 - 0.2 mg/1) were tested for shoot induction. Typically, ten explants were plated per Petri dish, cultured for 7-8 weeks, and analyzed for shoot regeneration efficiency assessed as the percentage of explants producing shoots per total number of explants plated.
  • BAP 6-bezylaminopurine
  • kinetin 0.5 - 1 mg/1
  • zeatin 0.5 - 1 mg/1
  • TDZ thidiazuron
  • auxins naphtaleneacetic acid (NAA;
  • Goldenseal (Hydrastis Canadensis). Goldenseal rhizomes were obtained from North Carolina Goldenseal and Ginseng Company (Marshall, NC) and transplanted into the Pro-Mix BX potting soil (Premier Tech Horticulture Company, Quakertown, PA). Leaf explants were excised from the 1-2 month-old plants, and surface sterilized by immersion in 70% ethanol for 1 min, followed by soaking in 1.5% sodium hypochlorite for 4-6 min.
  • MSR1 (1 mg/1 BAP and 0.1 mg/1 NAA)
  • MSR2 (1 mg/1 BAP; 1 mg/1 TDZ and 0.2 mg/1 NAA
  • MSR3 (1 mg/1 BAP; 0.5 mg/1 kinetin and 0.3 mg/1 NAA).
  • FIG. 1C illustrates Goldenseal shoots growing on the MSR4 elongation medium (0.4 mg/1 BAP).
  • MS media was supplemented with NAA, indole-3-acetic acid (IAA), indole- 3-butyric acid (IBA), or no hormones.
  • IAA indole-3-acetic acid
  • IBA indole- 3-butyric acid
  • the best root development was observed on the MS medium supplemented with 1 mg/1 IBA. Rooted plants were transferred to the Pro-Mix soil (Premier Tech Horticulture Company, Quakertown, PA). Morphology of the plants propagated in vitro was normal, that is, similar to that of the wild type plants.
  • Echinacea Echinacea purpurea
  • Calendula Calendula officinalis
  • Kalanchoe Kerata
  • Thyme Thymus vulgaris
  • Seeds of Echinacea, Calendula and Thyme were obtained from Horizon Herbs Co. (Williams, OR). All seeds were sterilized with 70% ethanol for 1 min followed by soaking in 1.5% sodium hypochlorite: for 10 min for Echinacea and Calendula, and 5 min for Thymus. After washing with sterile distilled water, 10-15 seeds of each medicinal plant were placed into the Magenta GA-7 box containing 40 ml of the MS-based germination medium supplemented with 10 g/1 sucrose and 7 g/1 agar. Stem segments with axillary buds were sub-cultured onto fresh MS media every 7-8 weeks.
  • FIG. 2 illustrates multiply shoot regeneration on MSR3 medium. The highest shoot regeneration efficiency of 36 % was observed on MSR3 medium. See Table 1.
  • Echinacea purpurea For regeneration, 10 day-old cotyledons and leaves from 2-month-old plants were cut into 4-5 mm explants and plated onto the regeneration medium.
  • FIG. 3 illustrates multiple shoots were produced from Echinacea explants after 5-6 weeks of culture. The highest regeneration efficiency of 84% and 81% was observed for MSR5 (1 mg/1 BAP, 0.5 mg/1 zeatin, 0.2 mg/1 NAA) and MSR7 (1 mg/1 BAP, 1 mg/1 thidiazuron, 0.3 mg/1 NAA), respectively. See Table 1. It was noticed that the cotyledon explants produced 2.5 times more shoots compare to the leaf explants.
  • Tropilab Inc. (St. Russia, FL). Leaves were surface sterilized by immersion in 70 % ethanol for 1 min, followed by soaking in 1.5% sodium hypochlorite for 8 min. After rinsing 3 times in sterile distilled water and blotting dry with the sterile filter paper, lx 1 cm leaf segments were transferred to the MS-based regeneration medium. The highest regeneration efficiency of 79% was observed on the MSR6 medium containing 2 mg/1 BAP, 0.1 mg/1 NAA, 30 g/1 sucrose and 7 g/1 agar (Table 1). The regenerated shoots were excised and transferred to MS medium. Shoots formed roots and produced whole plants within 3-5 weeks.
  • FIG. 4 illustrates development of multiple shoots from Kalanchoe leaf explants.
  • FIG. 5 illustrates shoot regeneration from Calendula. The best shoot regeneration of 48 % was observed on MSR3 medium. See Table 1.
  • a phenomenon of somaclonal variability is known to be induced by in vitro conditions for callus tissues or cell suspensions (Brown and Thorpe 1995 World J Microbiol Biotechnol 11: 409; Larkin and Scowcroft 1981 Theor Appl Genet 60: 197).
  • callus cultures and cell suspensions were initiated.
  • Leaf segments of each of Goldenseal, Echinacea, Kalanchoe, Thyme and Calendula were placed into the 100 x 15 mm Petri dishes containing MS-based callus induction medium. Plates were incubated in the dark at 24° C for 6-7 weeks.
  • FIG. 6A illustrates the Goldenseal callus grown on the MSCl medium.
  • MSCl medium was observed to be the most efficient.
  • Well-developed Goldenseal calli were selected and transferred to the callus propagation MSC2 medium (Table 1) and incubated in the dark.
  • FIG. 6B illustrates callus grown on MSC2 medium.
  • FIG. 6C illustrates the Goldenseal cell suspensions.
  • FIG. 6D illustrates shoot regeneration from callus tissues after 8 weeks of culturing on MSR3 medium.
  • the pBI121 vector containing the reporter GUS gene under control of the CaMV 35S promoter and the nptll gene under control of the NOS promoter were used (Jefferson et al. 1987 EMBO J 6: 3901).
  • the pBI121 was introduced into the Agrobacterium tumefaciens strain LBA4404.
  • Agrobacteria were grown at 28°C on solid LB media supplemented with 50 mg/1 kanamycin and 20 mg/1 rifampicin.
  • the bacterial cell suspension was prepared by inoculating 20 ml of the liquid LB medium with a single bacterial colony and grown for 1-2 days at 150 rpm in a shaker.
  • the suspension of Agrobacterium was diluted with a liquid MS medium to obtain ⁇ 0.5, 0.3 and 0.1.
  • Agrobacterium suspension ( ⁇ 0.5, 0.3 or 0.1) for 10 min.
  • ⁇ 0.5 was found the best for high transformation efficiency.
  • inoculation with Agrobacterium suspension diluted to ⁇ 0.1 resulted in the highest number of transformed plants.
  • the inoculated explants were transferred to the MS co-cultivation medium supplemented with 100 ⁇ acetosyringone, and incubated in the dark for 2 - 3 days at 24° C. It was further observed that 2 days of co-cultivation resulted in the highest transformation efficiency.
  • FIGS. 7A-7B illustrate effective selection of the Goldenseal transformants on the MST4 medium.
  • FIG. 7A illustrates development of the transgenic shoots on the MST4 medium in the presence of 30 mg/1 of kanamycin.
  • FIG. 7B illustrates the magnified shoot from FIG. 7A.
  • FIG. 8 illustrates the morphologically normal transgenic Goldenseal plants recovered from transformation and selection.
  • the first regeneration selection medium was MST7 supplemented with 30 mg/1 kanamycin
  • the second selection medium was MST8 supplemented with 50 mg/1 kanamycin (Table 1).
  • the Echinacea explants were transferred to MST8 medium, after 10-14 days of selection on the MST7 medium.
  • the kanamycin-resistant shoots of medicinal plants, 2-4 cm in length, developed on the selection media were excised and transferred to the root induction MST5 medium supplemented with 30 mg/1 kanamycin for Goldenseal, Thyme and Calendula, or the MS medium supplemented with 50 mg/1 kanamycin for Echinacea and Kalanchoe. Plantlets with roots were subsequently transferred to pots containing the Pro-Mix soil. Putative transgenic medicinal plants were tested for GUS expression by histochemical staining.
  • FIG. 9 illustrates histochemical GUS analysis of the transgenic Calendula plants. GUS activity in the transgenic Calendula plants was observed as the blue staining. Referring to FIG.
  • FIGS. 10A - IOC illustrate schematic drawings of binary pBI-based vectors prepared for stable transformation of plants via Agrobacterium tumefaciens.
  • the plasmid contains backbone of conventional pBI binary vector covalently linked to the T-DNA surrounded by the right border, RB, and the left border, LB.
  • the T-DNA includes the nptll gene for kanamycin selection.
  • the nptll gene is linked to the expression cassette that includes the Rubisco promoter, PrbcS or 35S promoter; the recombinant protein, the purification tag, Tag, the endoplasmic reticulum compartment sorting signal, KDEL, and the translation termination signal of the Rubisco gene, RbcT.
  • FIG.10A illustrates a vector for production of TBL-Fc protein.
  • FIG.10B illustrates a vector for cyanovirin (CNVR) microbicide generation.
  • FIG. IOC illustrates a vector designed production of the scytovirin (SCTV) microbicide.
  • the plasmid pBI121 containing the nptll gene driven by the NOS promoter for kanamycin selection and the reporter GUS gene driven by the CaMV 35S promoter was used for the development of the transformation protocol for callus tissues and cells.
  • PDS-1000/He system Bio-Rad, CA, USA. Briefly, 6 mg of 1.0-micron gold particles were transferred to the sterile Treff Eppendorf tube (Biochemical Resources International Inc., MA). 1 ml of 70% ethanol was added into the tube, and vortexed for at least 1 min. Particles were pelleted by centrifugation at 14,000 rpm for 2 min, the supernatant was removed and 1 ml sterile distilled water was added. After centrifugation at 14,000 rpm for 2 min., the supernatant was removed.
  • the following components were added to the Eppendorf tube containing gold particles: 20 ⁇ g plasmid DNA, 250 ⁇ of 2.5 M CaCh, 50 ⁇ of 0.1 M spermidine and 230 ⁇ sterile distilled water. The mixture was incubated on ice for 10 min. with frequent, gentle vortexing before centrifugation at 10,000 rpm for 1 min. The supernatant was carefully removed and particles were washed with 600 ⁇ of 100 % ethanol. After removal of the supernatant, the particles were suspended in 72 ⁇ of 100% ethanol and vortexed for 10 seconds. For each bombardment, 6 ⁇ of the DNA-gold suspension were spread over a macro carrier disk and air- dried in a laminar flow hood for 5 min.
  • callus cells were placed at the center (3 cm in diameter) of a Petri plate (100 mm) containing 20 ml of the callus propagation MSC2 medium (Table 1). The cells were bombarded with DNA- coated gold particles discharged with different rupture disk pressures (900 and 1100 psi) from 9.0 and 12.0 cm distance between the stopping screen and the target tissue. Cells were bombarded one or two times per plate. After 3-4 days of cultivation on MSC2 medium in the dark, callus cells were transferred to the selection MSC2 medium supplemented with 30 mg/1 or 50 mg/1 kanamycin. Callus was transferred every 3-4 weeks to fresh selection medium. After 5-6 weeks of selection, kanamycin-resistant clones were tested by the histochemical GUS assay.
  • Example 6 Production of the recombinant microbicides in Echinacea and Goldenseal
  • the HIV entry inhibitor cyanovirin, CNVR was chosen for production in Echinacea and Goldenseal expression systems (Huskens D and Schols D, 2012, Algal Lectins as Potential HIV Microbicide Candidates, Marine Drugs: 10, 1476-1497).
  • the Cyanovirin polypeptide PgCNVR-a designed for targeting into apoplast was as follows.
  • nucleic acid sequence encoding the recombinant CNVR protein was optimized for plant expression as follows:
  • FIG. 10B The transformation vector included the nptll gene for kanamycin selection of the transgenic plants.
  • the CaMV 35S promoter was used to drive the expression of the transgenes in leaves.
  • the Agrobacterium-mediated method described herein has been used in these experiments.
  • Scytovirin polypeptide PgSCTV-a, designed for targeting into the apoplast was as follows:
  • PNRCSNSKQCDGARTCSSSGFCQGTAGHAAA [SEQ ID NO: 3].
  • nucleic acid sequence encoding the recombinant SCTV protein was optimized for plant expression as follows:
  • FIG. IOC shows a schematic drawings of a vector for production of the SCTV microbicide.
  • Echinacea plants were produced after transformation and selection with this construct.
  • FIG. 11A illustrates selection of putative transgenic Echinacea shoots resistant to 50 mg/1 of kanamycin.
  • FIG. 11B illustrates target gene-specific PCR analysis of transgenic shoots.
  • FIG. ll C illustrates an example of the Western blot detection of the recombinant protein target using a polyclonal mouse primary antibody against the microbicide produced in E.coli. Binding of plant-derived microbicide to gpl20 of HIV-1 was determined by the sandwich ELISA assay.
  • the Nunc Maxisorp ELISA plates were coated overnight at 4°C with 100 ⁇ of the gpl20 protein (strain IIIB, Protein Sciences Corp., Meriden, CT) at 1 ⁇ g/ml in PBS, blocked for 1 h at room temperature with Blocking Buffer containing 3% BSA in PBS+0.05%Tween (PBS-T0.05), and washed 3 times with PBS.
  • Transgenic protein extracts 2 times diluted were added to PBS and incubated for 1 hour at room temperature.
  • Extracts were washed 3x with PBS following incubation with primary polyclonal mouse antiserum (Antibodies Incorporated, Davis, CA) against the microbicide expressed in E.coli diluted 1:1000 in Blocking Buffer for 1 hour at room temperature, followed by three washing with PBS-T and incubation with the secondary goat anti-mouse secondary antibody HRP-conjugate (1:10,000 dilution in Blocking Buffer) for one hour. Finally, plates were washed 3 times with PBS-T and lx with PBS. 100 ⁇ of SureBlue TMB Microwell Peroxidase Substrate (KPL, EMD Millipore Corp., Temecula, CA) were added and developed in the dark for 10 minutes.
  • KPL SureBlue TMB Microwell Peroxidase Substrate
  • FIG.1 ID illustrates that transgenic Echinacea plant expressed the recombinant CNVR protein that bind the HIV envelope protein gpl20.
  • the microbicides produced in Echinacea or Goldenseal may effectively inhibit HIV infection and can be used in the form of a minimally processed plant extract for anti-HIV preparations for direct vaginal application.
  • Example 7 Production of Anthrax-binding chimeric recombinant protein, TBL, fusion with Fc in Echinacea and Kalanchoe
  • FIG. 10A schematically represents a plant expression vector.
  • the vector includes a backbone derived from a conventional pBI binary vector covalently linked to the T-DNA surrounded by the right border, RB, and the left border, LB.
  • the T-DNA includes the nptll gene for kanamycin selection.
  • the nptll gene is linked to the expression cassette that includes the Rubisco promoter or CaM-35S promoter, PrbcS; the recombinant protein, the apoplast SP or endoplasmic reticulum compartment sorting signal, KDEL, and the translation termination signal of the Rubisco gene, RbcT.
  • the PgAlBl nucleic acid sequence encodes a variant of TBL polypeptide, the recombinant Anthrax Toxin Receptor polypeptide, fused with human IgG Fc,
  • the PgAlBl sequence optimized for expression in plants was as follows:
  • FIG. 12A illustrates the stringency of kanamycin selection. Referring to this figure, the transgenic shoots shown on the right side of the plate developed on the medium supplemented with kanamycin while the non- transgenic tissue shown on the left side of the plate died.
  • FIG. 12B illustrates a target- specific detection of the recombinant protein TBL in the extracts from the transgenic Kalanchoe plants by ELISA using the anti-human IgG peroxidase conjugate (Sigma, Cat. No. A-6089).
  • Echinacea plants Total and soluble plant proteins were extracted from transgenic Kalanchoe and Echinacea plants as described by Golovkin et al. 2007 Proc Natl Acad Sci USA 104: 6864. Plant tissue sample were collected, immediately frozen in liquid nitrogen and stored at -80° C until extraction. Recombinant product was extracted from frozen plant tissues directly using equal amount (V/W) of Laemmli loading buffer for the total/insoluble extract or soluble buffer containing 0.1 M Na phosphate pH 7.4, 0.3 M NaCl, 3% Glycerol, 0.1 mM ⁇ - ⁇ and 0.05 % of plant proteinase inhibitors cocktail (Sigma) for a total soluble protein, concentrated and brought into an equal volume of loading buffer.
  • V/W Laemmli loading buffer for the total/insoluble extract or soluble buffer containing 0.1 M Na phosphate pH 7.4, 0.3 M NaCl, 3% Glycerol, 0.1 mM ⁇ - ⁇ and 0.05 % of plant proteina
  • Example 8 Transient expression with viral vectors: development of plant-based vaccine against Smallpox.
  • a DNA fragment encoding vaccinia virus glycoprotein B5 membrane antigen was chosen for the transient production in planta. Goldenseal and Echinacea plants were used for transient transformation experiments.
  • a full extracellular antigenic domain (amino acids 20-275) of the vaccinia virus (W) strain WR that contains major neutralization epitopes of the B5 glycoprotein (42 kDa) was initially selected for optimization.
  • the B5 expression cassettes were designed to include C-terminal KDEL signals for ER targeting, c-Myc or His6 tags. Further optimization of the B5 extracellular antigenic domain that had no signal peptide transmembrane domain and cytoplasmic tail (Gene VACWR187) resulted in Pgl constructs.
  • B5/ Pgl expression cassettes The nucleic acid sequences encoding the B5 extracellular antigenic domain of EEV B5 Vaccinia virus glycoprotein (strain WR, GL29692293) that has no signal peptide (amino acids 20-275), transmembrane domain and cytoplasmic tail, harbors three N-linked glycosylation sites located within the short consensus repeats (SCR2) and includes four modular SCR domains (amino acids 20-237) and the stalk region (amino acids 238-275) harboring sites of major neutralization epitopes was optimized for expression in plants.
  • the plant optimized sequence was named pB5 (the plant optimized B5), or Pgl.
  • the nucleic acid sequence encoding the Pgl protein was as follows.
  • Electro- competent Agrobacterium cells were prepared in LB medium supplemented with 50 ⁇ g/ml rifampicin as overnight bacterial culture. The pelleted culture was washed twice with ice-cold sterile 10% glycerol and resuspended in 10 ml 10% glycerol to make 25 ⁇ aliquots frozen in liquid nitrogen and stored at -80°C.
  • plasmid DNA For electroporation, 1 ⁇ (0.1 ⁇ g) of plasmid DNA (Qiagen miniprep) was mixed with 25 ⁇ electrocompetent Agrobacterium cells strain GV3101 in LB medium supplemented with 25-50 ⁇ g/ml Gentamycin, 10 ⁇ g/ml rifampicin and electroporated. Following electroporation, samples were incubated in 1 ml LB for at least 2-3 hours at 28°C and at 120 rpm. The bacterial cells were plated onto selection LB media and incubated for 2-3 days at 28°C. Glycerol stocks for further use were prepared as 1:1 mix of 30 % sterile glycerol with fresh overnight bacterial culture and stored at -80°C.
  • One component ⁇ Agrobacterium cells carried genes encoding the PGl variants subcloned into the pICH11599 vector.
  • the expression cassettes that included genes of interest were subcloned into the pICH11599 within the polylinker for Ncol-Sacl, or Ncol-Hindlll, or NcoI-EcoRI restriction sites.
  • the other two components included the pre-manufactured vectors carrying either the targeting signal (cytosolic pICH10570) and the pICH10881 carrying the integrase as described in Giritch et al. 2006 Proc Natl Acad Sci U S A 103(40): 1470, which is incorporated herein by reference as if fully set forth.
  • the synthetic coding sequences were sub-cloned from the plasmid DNA supplied by synthesis facility Geneart (Life Technologies) and Genescript USA.
  • the pICH 11599 constructs were given the names of the corresponding sequences encoding antigenic proteins such as Pgl. All genes of interest included the ATG start codon within the 5' Ncol site. An additional amino acid could be added at the N-terminal end of the expressed protein.
  • constructs designed for expression in cytosol pICH10570
  • the protein was expressed from the first ATG of the cloned gene. All plasmids had a carbinicillin/ampicillin resistance gene for propagation in bacteria.
  • Three vector-based components were mixed and diluted at least ten times with the Infiltration Buffer (IB) (10 mM MES-NaOH; pH 5,5,;10 mM MgS0 4 ).
  • IB Infiltration Buffer
  • the pB5 protein was readily detected at 6-8 days postinfection in the leaf tissues of Goldenseal and Echinacea transfected with the B5 and apoplast-targeting construct.

Landscapes

  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des procédés de culture tissulaire et de propagation in vitro de plantes médicinales, en particulier, des plantes des genres Hydrastis, Echinacea, Kalanchoe, Thym et Calendula. L'invention concerne également des procédés visant à modifier génétiquement les plantes médicinales, ainsi que des procédés de production de protéines recombinantes de ces plantes. L'invention concerne de plus des compositions et des procédés d'administration de protéines recombinantes produites dans ces plantes à des sujets ayant besoin de ces protéines.
PCT/US2013/063086 2012-03-22 2013-10-02 Procédés et compositions pour la production de protéines recombinantes pharmaceutiques dans des plantes médicinales WO2014055659A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
IL237876A IL237876B (en) 2012-10-03 2015-03-22 Methods and compositions for production of recombinant pharmaceutical proteins in medicinal plants
US14/673,914 US20150197766A1 (en) 2012-03-22 2015-03-31 Methods and compositions for production of recombinant pharmaceutical proteins in medicinal plants
US16/012,394 US20180280461A1 (en) 2012-03-22 2018-06-19 Methods and compositions for production of recombinant pharmaceutical proteins in medicinal plants
IL261409A IL261409A (en) 2012-10-03 2018-08-27 Methods and compositions for production of recombinant pharmaceutical proteins in medicinal plants

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261709186P 2012-10-03 2012-10-03
US61/709,186 2012-10-03
US13/849,154 2013-03-22
US13/849,154 US9694068B2 (en) 2012-03-22 2013-03-22 Methods and compositions to produce vaccines against smallpox in plants
US13/922,719 US9913890B2 (en) 2012-06-22 2013-06-20 Methods and compositions for emergency post-infection treatment of anthrax
US13/922,719 2013-06-20

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US13/849,154 Continuation-In-Part US9694068B2 (en) 2012-03-22 2013-03-22 Methods and compositions to produce vaccines against smallpox in plants

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/673,914 Continuation US20150197766A1 (en) 2012-03-22 2015-03-31 Methods and compositions for production of recombinant pharmaceutical proteins in medicinal plants

Publications (1)

Publication Number Publication Date
WO2014055659A1 true WO2014055659A1 (fr) 2014-04-10

Family

ID=50435405

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/063086 WO2014055659A1 (fr) 2012-03-22 2013-10-02 Procédés et compositions pour la production de protéines recombinantes pharmaceutiques dans des plantes médicinales

Country Status (1)

Country Link
WO (1) WO2014055659A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104782494A (zh) * 2015-05-02 2015-07-22 冯文杰 一种百里香组培快繁方法
CN109496859A (zh) * 2018-11-30 2019-03-22 临沂大学 一种多肉植物红蛋水泡的组织培养方法
US20190174694A1 (en) * 2016-06-27 2019-06-13 Dümmen Group B.V. Ornamental Plant Displaying Compacted Plant Growth

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996024367A1 (fr) * 1995-02-06 1996-08-15 Bio Pharma Sciences B.V. Composition pharmaceutique pour le traitement de l'herpes
US20030180952A1 (en) * 2000-04-28 2003-09-25 Sugar Research & Development Corporation Plant regeneration
US20060075525A1 (en) * 2004-10-05 2006-04-06 Kin-Ying To Transgenic Echinacea plants
US7491798B2 (en) * 2002-05-16 2009-02-17 The United States Of America As Represented By The Department Of Health And Human Services Scytovirins and related conjugates, fusion proteins, nucleic acids, vectors, host cells, compositions, antibodies and methods of using scytovirins
US7754420B2 (en) * 1995-04-27 2010-07-13 The United States Of America As Represented By The Department Of Health And Human Services Methods of using cyanovirins to inhibit viral infection

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996024367A1 (fr) * 1995-02-06 1996-08-15 Bio Pharma Sciences B.V. Composition pharmaceutique pour le traitement de l'herpes
US7754420B2 (en) * 1995-04-27 2010-07-13 The United States Of America As Represented By The Department Of Health And Human Services Methods of using cyanovirins to inhibit viral infection
US20030180952A1 (en) * 2000-04-28 2003-09-25 Sugar Research & Development Corporation Plant regeneration
US7491798B2 (en) * 2002-05-16 2009-02-17 The United States Of America As Represented By The Department Of Health And Human Services Scytovirins and related conjugates, fusion proteins, nucleic acids, vectors, host cells, compositions, antibodies and methods of using scytovirins
US20060075525A1 (en) * 2004-10-05 2006-04-06 Kin-Ying To Transgenic Echinacea plants

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KHAN, MOHAMMAD YASEEN ET AL.: "Recent advances in medicinal plant biotechnol ogy", INDIAN JOURNAL OF BIOTECHNOLOGY, vol. 8, January 2009 (2009-01-01), pages 9 - 22 *
SEXTON, AMY ET AL.: "Transgenic plant production of Cyanovirin-N, an HIV mic robicide", FASEB JOURNAL, vol. 20, no. 2, February 2006 (2006-02-01), pages 356 - 358 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104782494A (zh) * 2015-05-02 2015-07-22 冯文杰 一种百里香组培快繁方法
US20190174694A1 (en) * 2016-06-27 2019-06-13 Dümmen Group B.V. Ornamental Plant Displaying Compacted Plant Growth
CN109496859A (zh) * 2018-11-30 2019-03-22 临沂大学 一种多肉植物红蛋水泡的组织培养方法

Similar Documents

Publication Publication Date Title
Abiri et al. A critical review of the concept of transgenic plants: insights into pharmaceutical biotechnology and molecular farming
O'Keefe et al. Engineering soya bean seeds as a scalable platform to produce cyanovirin‐N, a non‐ARV microbicide against HIV
US20080279877A1 (en) HPV antigens, vaccine compositions, and related methods
Ganapathi et al. Tobacco (Nicotiana tabacum L.)-A model system for tissue culture interventions and genetic engineering
JP2008194054A (ja) 植物における防御タンパク質を含む免疫グロブリンの製造法およびその使用
PT2374892T (pt) Expressão de proteínas virais em plantas
ES2461941T3 (es) Método para la producción de proteínas recombinantes a partir de raíces pilosas de plantas
Rosales-Mendoza et al. Transgenic carrot tap roots expressing an immunogenic F1–V fusion protein from Yersinia pestis are immunogenic in mice
KR20100044813A (ko) 돼지 부종병 백신
US20050155113A1 (en) Vectors and methods for immunization against Norwalk virus using transgenic plants
JP7233662B2 (ja) グリコシル化したａｇ８５ａタンパク質を含む結核予防用ワクチン組成物およびその製造方法
JP2005522998A (ja) 毒性および病原体が媒介する疾患を治療しかつ予防するための新規イムノアドヘシン
WO2014055659A1 (fr) Procédés et compositions pour la production de protéines recombinantes pharmaceutiques dans des plantes médicinales
Noris et al. A human papillomavirus 8 E7 protein produced in plants is able to trigger the mouse immune system and delay the development of skin lesions
JP5008811B2 (ja) ライノウイルス感染を防止するための免疫接着物
EP1147178A1 (fr) Production de peptides et de proteines biomedicaux dans les plantes par utilisation des systemes de transcomplementation
Baranski et al. Genetic engineering of carrot
US20170239345A1 (en) Methods and compositions to produce vaccines against smallpox in plants
US20180280461A1 (en) Methods and compositions for production of recombinant pharmaceutical proteins in medicinal plants
US20150197766A1 (en) Methods and compositions for production of recombinant pharmaceutical proteins in medicinal plants
Loc et al. Expression of the Escherichia coli heat-labile enterotoxin B subunit in transgenic watercress (Nasturtium officinale L.)
TW201139672A (en) Immunization of fish with plant-expressed recombinant proteins
Romero-Maldonado et al. Expression in plants of two new antigens with implications in Alzheimer’s disease immunotherapy
US8148609B2 (en) Uses for Yerba Santa
WO2011010337A1 (fr) Vaccins à base de chimère génétique d’antigènes viraux et/ou tumoraux et de protéines végétales

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13843103

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 237876

Country of ref document: IL

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC, FORM 1205A DATED 06-08-2015

122 Ep: pct application non-entry in european phase

Ref document number: 13843103

Country of ref document: EP

Kind code of ref document: A1